These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8314955)

  • 21. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intensive care and treatment of severe ovarian hyperstimulation syndrome].
    Ma MY; Wen WB; Zhou LX; Yu TO; Fang B
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1212-4. PubMed ID: 15485803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian hyperstimulation syndrome due to exogenous gonadotropin administration.
    Bider D; Menashe Y; Oelsner G; Serr DM; Mashiach S; Ben-Rafael Z
    Acta Obstet Gynecol Scand; 1989; 68(6):511-4. PubMed ID: 2520805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can we eliminate severe ovarian hyperstimulation syndrome? Not completely.
    Buckett W; Chian RC; Tan SL
    Hum Reprod; 2005 Aug; 20(8):2367; author reply 2367-8. PubMed ID: 16024544
    [No Abstract]   [Full Text] [Related]  

  • 25. Ovarian hyperstimulation syndrome.
    McElhinney B; McClure N
    Baillieres Best Pract Res Clin Obstet Gynaecol; 2000 Feb; 14(1):103-22. PubMed ID: 10789263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early hCG administration as an alternative prevention strategy of ovarian hyperstimulation syndrome during an IVF cycle.
    Son WY; Dahan MH; Monnier P; Holzer H; Nayot D
    Minerva Ginecol; 2017 Apr; 69(2):207-209. PubMed ID: 28150929
    [No Abstract]   [Full Text] [Related]  

  • 27. Ovarian hyperstimulation syndrome.
    Balen A
    Hum Fertil (Camb); 2013 Sep; 16(3):143. PubMed ID: 23944686
    [No Abstract]   [Full Text] [Related]  

  • 28. Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient.
    Levy T; Orvieto R; Homburg R; Peleg D; Dekel A; Ben-Rafael Z
    Hum Reprod; 1996 Jun; 11(6):1177-9. PubMed ID: 8671418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agonist trigger: what is the best approach? Agonist trigger and low dose hCG.
    Humaidan P
    Fertil Steril; 2012 Mar; 97(3):529-30. PubMed ID: 22154368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian hyperstimulation syndrome manifests as acute unilateral hydrothorax.
    Daniel Y; Yaron Y; Oren M; Peyser MR; Lessing JB
    Hum Reprod; 1995 Jul; 10(7):1684-5. PubMed ID: 8582961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
    van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
    Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?
    Lee C; Tummon I; Martin J; Nisker J; Power S; Tekpetey F
    Hum Reprod; 1998 May; 13(5):1157-8. PubMed ID: 9647538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GnRH-agonist triggering to avoid ovarian hyperstimulation syndrome: a review of the evidence.
    Martinez MC; Ruiz FJ; García-Velasco JA
    Curr Drug Targets; 2013 Jul; 14(8):843-9. PubMed ID: 23614678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is multiple pregnancy an unavoidable complication of ovulation induction? The case for pulsatile GnRH.
    Filicori M; Cognigni GE; Arnone R; Carbone F; Falbo A; Tabarelli C; Pari C; Ciampaglia W; Casadio P; Spettoli D; Pecorari R
    Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 65 Suppl():S19-21. PubMed ID: 8735007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous albumin and the prevention of severe ovarian hyperstimulation syndrome.
    Ben-Rafael Z; Orvieto R; Dekel A; Peleg D; Gruzman C
    Hum Reprod; 1995 Oct; 10(10):2750-2. PubMed ID: 8567807
    [No Abstract]   [Full Text] [Related]  

  • 36. Long hospitalization for severe ovarian hyperstimulation syndrome with persistent right hydrothorax and two occurrences of pneumonia.
    Lin J; Li X; Zhang L
    Int J Gynaecol Obstet; 2017 Mar; 136(3):350-352. PubMed ID: 28099716
    [No Abstract]   [Full Text] [Related]  

  • 37. Liver dysfunction in severe ovarian hyperstimulation syndrome.
    Obrzut B; Kuczyński W; Grygoruk C; Putowski L; Kluz S; Skret A
    Gynecol Endocrinol; 2005 Jul; 21(1):45-9. PubMed ID: 16048801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of cabergoline for prevention of ovarian hyperstimulation syndrome in assisted reproductive technologies].
    Kozovski G; Angelova M; Kacarova P
    Akush Ginekol (Sofiia); 2014; 53(5):34-5. PubMed ID: 25558669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe ovarian hyperstimulation syndrome following salvage of empty follicle syndrome.
    Evbuomwan IO; Fenwick JD; Shiels R; Herbert M; Murdoch AP
    Hum Reprod; 1999 Jul; 14(7):1707-9. PubMed ID: 10402372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Controlled ovarian hyperstimulation in an in vitro fertilization program. Results and prevention of complications].
    Grochowski D
    Ginekol Pol; 2000 Oct; 71(10):1293-6. PubMed ID: 11143940
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.